The inhibition of the interaction of MDM2 with p53 is a rational therapeutic strategy that has been shown to lead to an increase in the levels of p53 and induce cell cycle arrest and apoptosis in cancer cells in vitro [52]. The gene discussed is TP53; the disease is cancer.